Advanced medicines may remain elusive to India's HIV-infected children

Kids have been long neglected by pharma firms because their number is much less compared to adults suffering from HIV, and so there is little money to be made

Photo: Shutterstock

Worried by the repeated shortage of medicines to control human immunodeficiency virus or HIV in infants, health activists and researchers are unclear about the availability of a 4-in-1 drug combination, which is an improvement over the existing HIV drugs for infants in India.   Even the National AIDS Control Organisation (NACO), a government body that manages India’s HIV and Acquired Immunodeficiency Syndrome or AIDS control programme, is concerned.   That is mainly because Cipla, a Mumbai-based multinational company, which makes HIV drugs for infants, has not been able to ...